A Review of its Pharmacological Properties and Therapeutic Efficacy in Neutropenia and Related Clinical Settings | Semantic Scholar (2024)

There were no differences in the incidence and severity of adverse events, including skeletal pain, between single-dose pegfilgrastim and daily fil grastim in patients with nonmyeloid cancer receiving myelosuppressive chemotherapy.

CT and tear G-CSF improved the predictive model for CAD when added to cardiovascular CRF in a sample of symptomatic patients and further studies are needed for validation of these findings in asymptomatic patients.

CT and tear G-CSF improved the predictive model for CAD when added to cardiovascular CRF in patients with acute coronary cardiopathy suspicion in the authors' sample of symptomatic patients.

An overview of publication activity is presented, considering a IuPhar/BPS-curated list of targets with restriction to pain-related publications, which was also used to identify topics.

Experimental and in silico analyses provided good information regarding the function and characteristics of the recombinant G-CSF which could be useful for industrial researches.

This articles attempts to provide an overview of the recombinant biopharmaceutical products available in the market and their contribution towards improving human health.

A comprehensive biomathematical model to explain the dynamics of granulopoiesis under chemotherapy and applications of two different G-CSF derivatives is established.

Lenograstim is a glycosylated form of recombinant human G-CSF, more similar to the endogenous cytokine, which is compelling in some well-defined settings (highly myelosuppressive chemotherapy, advanced cancer, high-risk patients).

...

...

The reduced function and reduced expression of FCRIII suggests the presence of immature neutrophils in patients receiving rG-CSF post BMT, and the ability to phagocytose bacteria in cells from patients receiving G- CSF was reduced.

The duration of neutropenia and hospitalisation were both lower in patients who received lenograstim compared with no treatment, and savings were largely attributable to decreased expenditure on hospitalisation in the lenogsrastim-treated group.

The G-CSF group received a significantly higher dose-intensity than the control group, with the greatest difference in the first three cycles, and had a better 2-year survival rate than controls.

Lenogastrim produced sustained neurotrophil recovery in patients with congenital agranulocytosis, decreased the incidence and severity of infection and improved the quality of life.

A simplified mobilization protocol is described that requires only one apheresis to achieve rapid hematologic engraftment and led to more rapid neutrophil recovery, markedly accelerated platelet recovery, less use of antimicrobial agents and parenteral nutrition, and more than 10 days earlier discharge from hospital.

Clinically, multiple alkylating agent‐based regimens requiring intensive supportive care and associated with substantial morbidity and an appreciable mortality risk are given as consolidation after an initial period of standard outpatient therapy.

Use of CSFs has made HDCT a procedure that is better tolerated, more convenient to use on a large scale, and probably cheaper, and protocols for HDGT incorporating the use of CSF are becoming routine.

Lenograstim stimulated neutrophil colony formation at doses 16 times lower than that of the 2 nonglycosylated rG-CSFs and was twice as potent as filgrastim at maximal colony stimulation, suggesting that glycosylation gives lenograstIM a potency advantage.

It is suggested that a short course of rHuG-CSF is beneficial in increasing the stem cell collection and induced a tenfold increase in the circulating CFU-GM amongst which immature progenitors, estimated by the Delta assay, are detected.

...

...